Table 2

Association analyses for rs8192772 and rs2480256 in stage II and the combined two stages

No.

SNP

Controls

Cases

Crude OR (95% CI)

Crude P

Adjusted OR (95% CI)

Adjusted P

rs8192772

allelic

T

621

925

1.105 (0.886 to 1.378)

0.375

1.057 (0.945 to 1.182)

0.331

C

161

265

geonotypic

T/T+T/C

242 + 137

365 + 195

1.973 (1.012 to 3.852)

0.043

1.433 (1.023 to 2.009)

0.037

C/C

12

35

Stage II

rs2480256

allelic

G

467

641

1.231(1.025 to 1.480)

0.026

1.115 (1.016 to 1.223)

0.022

A

313

529

geonotypic

G/G+G/A

140 + 187

191 + 259

1.557 (1.118 to 2.169)

0.008

1.256 (1.062 to 1.485)

0.008

A/A

63

135

rs8192772

allelic

T

1,075

1,348

1.039 (0.873 to 1.237)

0.667

1.045 (0.946 to 1.154)

0.384

C

283

368

geonotypic

T/T+T/C

413 + 249

539 + 271

2.356 (1.344 to 4.129)

0.002

1.820 (1.330 to 2.490)

1.81E-04

C/C

17

49

Stage I + Stage II

rs2480256

allelic

G

827

936

1.62 (1.092 to 1.460)

0.002

1.165 (1.073 to 1.265)

2.75E-04

A

529

756

geonotypic

G/G+G/A

246 + 335

284 + 368

1.782 (1.363 to 2.330)

2.07E-05

1.464 (1.259 to 1.702)

7.48E-07

A/A

97

194

Haplotype rs8192772-rs2480256

Frequency in the Control

Frequency in the SLE

OR (95% CI)

P-value

TG

60.36%

54.00%

0.771 (0.668 to 0.890)

0.0004

TA

18.75%

24.46%

1.407 (1.182 to 1.675)

0.0001

CA

20.14%

20.05%

0.994 (0.833 to 1.186)

0.944

CI, confidence interval; OR, odds ratio; SLE, systemic lupus erythematosis; SNP, single nucleotide polymorphism.

Liao et al. Arthritis Research & Therapy 2011 13:R11   doi:10.1186/ar3232